127 related articles for article (PubMed ID: 30011108)
1. Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US.
Chuang CC; Yang E; Zou KH; Araiza A; Wang A; Luo X
Int J Clin Pract; 2019 Aug; 73(8):e13207. PubMed ID: 30011108
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
3. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage.
Cisternas MG; Foreman AJ; Marshall TS; Runken MC; Kobashi KC; Seifeldin R
Curr Med Res Opin; 2009 Apr; 25(4):911-9. PubMed ID: 19250059
[TBL] [Abstract][Full Text] [Related]
4. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
5. Real-world characteristics of elderly patients with overactive bladder in the United States.
Ganz ML; Liu J; Zou KH; Bhagnani T; Luo X
Curr Med Res Opin; 2016 Dec; 32(12):1997-2005. PubMed ID: 27645532
[TBL] [Abstract][Full Text] [Related]
6. Impact of coexisting overactive bladder in Medicare patients with osteoporosis.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; Kirby C; Abbott P
Arch Gerontol Geriatr; 2018; 75():44-50. PubMed ID: 29180131
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, management and outcomes of medically complex vulnerable elderly patients with urinary incontinence in the United States.
Luo X; Chuang CC; Yang E; Zou KH; Araiza AL; Bhagnani T
Int J Clin Pract; 2015 Dec; 69(12):1517-24. PubMed ID: 26355637
[TBL] [Abstract][Full Text] [Related]
8. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
9. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
10. Health-related consequences of overactive bladder.
Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States.
Durden E; Walker D; Gray S; Fowler R; Juneau P; Gooch K
Neurourol Urodyn; 2018 Jun; 37(5):1641-1649. PubMed ID: 29464813
[TBL] [Abstract][Full Text] [Related]
12. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
[TBL] [Abstract][Full Text] [Related]
13. Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.
Suehs BT; Davis C; Ng DB; Gooch K
Drugs Aging; 2017 Jul; 34(7):535-543. PubMed ID: 28540648
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of overactive bladder syndrome in six Western countries.
Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
[TBL] [Abstract][Full Text] [Related]
15. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
16. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Kachru N; Sura S; Chatterjee S; Aparasu RR
Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
[TBL] [Abstract][Full Text] [Related]
17. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
18. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
19. Vulnerable elderly patients and overactive bladder syndrome.
Kraus SR; Bavendam T; Brake T; Griebling TL
Drugs Aging; 2010 Sep; 27(9):697-713. PubMed ID: 20809661
[TBL] [Abstract][Full Text] [Related]
20. The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States.
Durden E; Walker D; Gray S; Fowler R; Juneau P; Gooch K
J Occup Environ Med; 2018 Sep; 60(9):847-852. PubMed ID: 29851742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
